PART 04: Introduction
• Key market highlights
• Pipeline analysis PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis PART 06: Regulatory approval
• Orphan drug legislation PART 07: Market segmentation by product type
• Biologics
• Non-biologics PART 08: Geographical segmentation
• Orphan drugs market in Americas
• Orphan drugs market in EMEA
• Orphan Drugs Market in APAC PART 09: Decision framework PART 10: Drivers and challenges
• Market Drivers
• Impact of drivers on key customer segments
• Market Challenges
• Impact of challenges on key customer segments PART 11: Market trends
• Emerging applications for orphan drug development
• Increasing focus on development of biologics
• Repurposing of non-orphan drugs to orphan drugs PART 12: Competitive Scenario
• Vendor landscape PART 13: Key vendor analysis
• AbbVie
• Celgene
• F. Hoffmann La Roche
• Novartis
• Other prominent vendors PART 14: Appendix
• List of Abbreviations List of Exhibits Exhibit 01: Overview of phase III molecules for few vendors Exhibit 02: Pipeline overview based on different therapies Exhibit 03: Pipeline analysis Exhibit 04: Global orphan drugs market snapshot Exhibit 05: Orphan drug requests ' year-over-year growth 2014-2016 Exhibit 06: Few breakthroughs in global orphan drugs market 2014-2016 Exhibit 07: Global orphan drugs market 2016-2021($ billions) Exhibit 08: Opportunity analysis in global orphan drugs market Exhibit 09: Five forces analysis Exhibit 10: Global orphan drugs market segmentation based on product type Exhibit 11: Increasing trend of approval of biologics Exhibit 12: Global orphan drugs market for biologics 2016-2021($ billions) Exhibit 13: Few significant non-biologics approved as orphan drugs